FrancophonIA/ELRC3.0 huggingface dataset:
English: However, co-administration of doravirine and the sensitive CYP3A substrate midazolam resulted in a 18 % decrease in midazolam exposure, suggesting that doravirine may be a weak CYP3A inducer.
Maltese: Madankollu, l-għoti ta' doravirine flimkien mas-sustrat sensittiv ta' CYP3A midazolam wassal għal tnaqqis ta' 18 % fl-esponiment għal midazolam, li jissuġġerixxi li doravirine jista' jkun induttur dgħajjef ta' CYP3A.
English: Doravirine There is no information on potential acute symptoms and signs of overdose with doravirine.
Maltese: M'hemm l-ebda informazzjoni dwar is-sintomi u s-sinjali akuti possibbli ta' doża eċċessiva b'doravirine.
English: Doravirine does not inhibit the human cellular DNA polymerases α, ß, and mitochondrial DNA polymerase γ.
Maltese: Dawn il-prodotti mediċinali jinkludu, iżda mhumiex limitati għal dawn li ġejjin:
English: In the DRIVE-SHIFT trial, an immediate switch to Delstrigo was demonstrated to be non-inferior at Week 48 compared to continuation of the baseline regimen at Week 24 as assessed by the proportion of subjects with HIV-1 RNA < 40 copies/mL.
Maltese: Fil-prova DRIVE-SHIFT, bidla immedjata għal Delstrigo ntweriet li ma kinitx inferjuri f'Ġimgħa 48 meta mqabbla mat-tkomplija tal-iskeda ta' trattament tal-linja bażi f'Ġimgħa 24 kif stmat millproporzjon ta' individwi b'RNA ta' HIV-1 ta' < 40 kopja/mL.
English: Antidiabetics metformin (1000 mg SD, doravirine 100 mg QD)
Maltese: (1000 mg SD, doravirine 100 mg QD)
English: A moderate amount of data on pregnant women (between 300-1,000 pregnancy outcomes) indicate no malformations or foetal/neonatal toxicity associated with tenofovir disoproxil.
Maltese: Ammont moderat ta' data dwar nisa tqal (bejn 300-1,000 riżultat ta' tqala) ma jindika l-ebda formazzjonijiet ħżiena jew tossiċità fil-fetu/wara t-twelid assoċjati ma' tenofovir disoproxil.
English: • regular clinical and laboratory screening for cytomegalovirus (CMV) infection.
Maltese: • skrining regolari kliniku u fil-laboratorju għal infezzjoni b'cytomegalovajrus(CMV).
English: • prophylaxis for Pneumocystis jirovecii pneumonia (PJP) to all patients throughout treatment;
Maltese: • profilassi għal pulmonitePneumocystis jirovecii(PJP) għall-pazjenti kollha matul il-kura;
English: The PRAC considered the very limited new safety data from three studies (GS-US-312-0123, GSUS-313-0124, GS-US-313-0125), now terminated, evaluating the addition of idelalisib to standard therapies in first line CLL and relapsed indolent non-Hodgkin lymphoma (iNHL)/small lymphocytic lymphoma (SLL).
Maltese: Il-PRAC qies id-data ġdida limitata ħafna dwar is-sigurtà minn tliet studji (GS-US-312-0123, GS-US313-0124, GS-US-313-0125), li issa spiċċaw, li vvalutaw iż-żieda ta' idelalisib ma' terapiji standard f'CLL tal-ewwel linja u f'rikaduta ta' limfoma mhux ta' Hodgkin indolenti (iNHL)/limfoma limfoċitika żgħira (SLL).
English: • The PRAC considered the provisional measure under Article 20(3) of Regulation (EC) No 726/2004 in the framework of Article 20 of Regulation (EC) No 726/2004 procedure resulting from pharmacovigilance data for Zydelig (idelalisib).
Maltese: • Il-PRAC qies il-miżura provviżorja skont l-Artikolu20(3) tar-Regolament(KE) Nru726/2004 filqafas tal-proċedura skont l-Artikolu 20 tar-Regolament (KE) Nru 726/2004 bħala riżultat taddata dwar il-farmakoviġilanza għal Zydelig (idelalisib).
English: • The PRAC noted that most of the serious adverse events reported in studies 0123, -0124 and -0125 were related to infections.
Maltese: • Il-PRAC innota li ħafna mill-avvenimenti avversi serji rrapportati fl-istudji 0123, -0124 u -0125 kienu relatati ma' infezzjonijiet.
English: • The PRAC reviewed the very limited and preliminary data provided by the marketing authorisation holder on the interim results of study GS-US-312-0123, GS-US-313-0124, GS-US-313-0125 that suggested an increased risk of death and serious infection with idelalisib.
Maltese: • Il-PRAC irrieżamina d-data limitata ħafna u preliminari pprovduta mid-detentur talawtorizzazzjoni għat-tqegħid fis-suq dwar ir-riżultati interim tal-istudju GS-US-312-0123, GSUS-313-0124, GS-US-313-0125 li ssuġġerew żieda akbar fir-riskju ta' mewt u infezzjoni serja b'idelalisib.
English: Zydelig (Idelalisib) is a centrally authorised product and is currently indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
Maltese: Zydelig (Idelalisib) huwa prodott awtorizzat skont proċedura ċentralizzata u attwalment huwa indikat flimkien ma' rituximab għal-kura ta' pazjenti adulti b'lewkimja limfoċitika kronika (CLL) li talanqas ikunu rċevew terapija waħda preċedenti, jew bħala kura tal-ewwel għażla fil-preżenza ta' tħassir ta' 17p jew ta' mutazzjoni ta' TP53 f'pazjenti li l-kimoimmunoterapija mhijiex adatta għalihom.
English: • monitoring for respiratory signs and symptoms of throughout treatment and reporting of new respiratory symptoms;
Maltese: • monitoraġġ għal sinjali u sintomi respiratorji matul il-kura u r-rappurtar ta' sintomi respiratorji ġodda;
English: This recommendation is without prejudice to the final conclusions of the ongoing procedure under Article 20 of Regulation (EC) 726/2004.
Maltese: Din ir-rakkomandazzjoni hija mingħajr preġudizzju għall-konklużjonijiet finali tal-proċedura għaddejja skont l-Artikolu 20 tar-Regolament (KE) 726/2004.
English: The MAH suggested that in studies -0123, -0124 and -0125 lines of therapy (i.e. increased risk in earlier stages of disease) and concomitant medication (such as bendamustine) may have increased the risk of infection.
Maltese: IlMAH issuġġerixxa li fl-istudji -0123, -0124 u -0125, ir-reġimen ta' terapija (jiġifieri riskju ogħla flistadji aktar bikrin tal-marda) u l-medikazzjoni konkomitanti (bħal bendamustine) setgħu żiedu r-riskju ta' infezzjoni.
English: The current recommendation relates only to provisional measures recommended by the PRAC for idelalisib.
Maltese: Ir-rakkomandazzjoni attwali tikkonċerna biss il-miżuri provviżorji rakkomandati mill-PRAC għal idelalisib.
English: Also, post-marketing reports of adverse events in EudraVigilance indicate that infections (including sepsis and pneumocystis) account for a large proportion of reported cases, including fatal cases.
Maltese: Barra minn hekk, ir-rapporti ta' wara t-tqegħid fis-suq ta' avvenimenti avversi fl-EudraVigilance jindikaw li infezzjonijiet (li jinkludu sepsis u pneumocystis) jirrappreżentaw proporzjon kbir tal-każijiet irrapportati, inklużi każijiet fatali.
English: Regular clinical and laboratory screening for cytomegalovirus should also be performed.
Maltese: Għandu jsir ukoll skrinjar regolari kliniku u fil-laboratorju għaċ-ċitomegalovajrus.
English: Similarly, studies -0124 and -0125 are not consistent with the FL indication because idelalisib was combined with rituximab or rituximab and bendamustine, respectively, which are not authorised combinations.
Maltese: Bl-istess mod, l-istudji -0124 u -0125 mhumiex konsistenti malindikazzjoni ta' FL minħabba li idelalisib kien ġie kkombinat ma' rituximab jew rituximab u bendamustine, rispettivament, li mhumiex kombinazzjonijiet awtorizzati.
English: Idelalisib is also indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
Maltese: Idelalisib huwa indikat ukoll bħala monoterapija għall-kura ta' pazjenti adulti b'limfoma follikulari (FL) rifrattarja wara żewġ reġimi ta' kura preċedenti.
English: It is to be noted that the data currently available to the PRAC is very limited and does not enable the PRAC to give definite conclusions.
Maltese: Għandu jiġi nnotat li d-data attwalment disponibbli għall-PRAC hija limitata ħafna u ma tippermettix li l-PRAC jagħti konklużjonijiet definittivi.
English: Based on the inhibitory effects of idelalisib on the PI3K pathway, it is possible that the increased risk of serious infection observed in studies 0123, -0124 and -0125 could be relevant to the authorised indications.
Maltese: Abbażi tal-effetti inibitorji ta' idelalisib fuq il-passaġġ PI3K, huwa possibbli li r-riskju akbar ta' infezzjoni serja osservat fl-istudji 0123, -0124 u -0125 jista' jkun rilevanti għall-indikazzjonijiet awtorizzati.
English: The trials evaluated combinations with chemotherapy and immunotherapy which are currently not authorised for Zydelig (idelalisib), or authorised combination of Zydelig and immunotherapy but in a population with earlier disease characteristics than the currently approved indication.
Maltese: Il-provi vvalutaw kombinazzjonijiet b'kimoterapija u b'immunoterapija li attwalment mhumiex awtorizzati għal Zydelig (idelalisib), jew kombinazzjoni awtorizzata ta' Zydelig u immunoterapija iżda f'popolazzjoni b'karatteristiċi ta' stadji aktar bikrin tal-marda mill-indikazzjoni attwalment approvata.
English: On 10 March 2016, the European Commission was informed that an increased risk of death and higher incidence of serious adverse events (SAE) among subjects receiving idelalisib compared to the control groups had been observed in three clinical trials by the Independent Safety Data Monitoring group.
Maltese: Fl-10 ta' Marzu 2016, il-Kummissjoni Ewropea ġiet infurmata li fi tliet provi kliniċi, il-grupp Indipendenti ta' Monitoraġġ tas-Sikurezza tad-Deata kien osserva riskju akbar ta' mewt u inċidenza ogħla ta' avvenimenti avversi serji (SAE) fost individwi li kienu qed jirċievu idelalisib meta mqabbla mal-gruppi ta' kontroll.
English: The PRAC took into account the data submitted by the marketing authorisation holder (MAH).
Maltese: Il-PRAC qies id-data ppreżentata mid-detentur tal-awtorizzazzjoni għat-tqegħid fuq is-suq (MAH).
English: On 11 March 2016 the EC therefore triggered a procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data, and requested the PRAC to assess the impact of the above concerns on the benefit-risk balance of Zydelig (idelalisib) and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked.
Maltese: Għalhekk fil-11 ta' Marzu 2016, il-KE tat bidu għal proċedura skont l-Artikolu 20 tar-Regolament (KE) Nru 726/2004 bħala riżultat tad-data dwar il-farmakoviġilanza, u talbet lill-PRAC jevalwa l-impatt tattħassib imsemmi hawn fuq dwar il-bilanċ tal-benefiċċju-riskju ta' Zydelig (idelalisib) u biex joħroġ rakkomandazzjoni dwar jekk l-awtorizzazzjonijiet rilevanti għat-tqegħid fis-suq għandhomx jinżammu, jiġu varjati, sospiżi jew revokati.
English: The PRAC noted that in study -0123, idelalisib was administered in combination with bendamustine and rituximab (which is not an authorised combination) and CLL patients were previously untreated, which is not consistent with the current CLL indication.
Maltese: Il-PRAC innota li fl-istudju -0123, idelalisib kien ingħata f'kombinazzjoni ma' bendamustine u ma' rituximab (li mhijiex kombinazzjoni awtorizzata) u l-pazjenti b'CLL ma kinux ingħataw kura preċedenti, li mhuwiex konsistenti malindikazzjoni attwali ta' CLL.
English: • monitoring of absolute neutrophil counts (ANC) in all patients at least every two weeks for the first six months of treatment with idelalisib, and at least weekly in patients while ANC is less than 1,000 per mm3.
Maltese: • monitoraġġ tal-għadd assolut ta' newtrofili (ANC) fil-pazjenti kollha talanqas kull ħmistax għallewwel sitt xhur ta' kura b'idelalisib, u talanqas darba fil-ġimgħa f'pazjenti waqt li l-ANC ikun ta' inqas minn 1,000 għal kull mm3.
English: The PRAC therefore proposed risk minimisation measures, including amendments to the product information and a communication to healthcare professionals.
Maltese: Għalhekk il-PRAC ippropona miżuri tal-minimizzazzjoni tar-riskju, fosthom emendi għallinformazzjoni dwar il-prodott u komunikazzjoni lill-professjonisti fil-qasam tal-kura tas-saħħa.
English: The reason why patients in the earlier stages of disease might be at increased risk of death and serious infection with idelalisib is not clear, although it is likely that there is an interaction between benefit-risk balance in differing populations and their level of disease-related mortality.
Maltese: Ir-raġuni għaliex il-pazjenti fi stadji aktar bikrin tal-mard jistgħu jkunu f'riskju akbar ta' mewt u infezzjoni serja b'idelalisib mhijiex ċara, għalkemm huwa possibbli li hemm interazzjoni bejn ilbilanċ tal-benefiċċju-riskju f'popolazzjonijiet differenti u l-livell tal-mortalità tagħhom relatata malmarda.
English: The PRAC also considered available safety data from clinical trials submitted in support of the initial marketing authorisation and extensions of indication and Eudravigilance data in relation to the overall risk of treatment with idelalisib.
Maltese: Il-PRAC qies ukoll id-data dwar is-sigurtà disponibbli minn provi kliniċi li ġew ippreżentati f'appoġġ għall-awtorizzazzjoni inizjali għat-tqegħid fis-suq u l-estensjonijiet talindikazzjoni u d-data fil-Eudravigilance fir-rigward tar-riskju ġenerali ta' kura b'idelalisib.
English: However, in light of the emerging safety data, the European Commission (EC) considered that the findings from the clinical trials and all available safety data related to idelalisib should be reviewed in order to assess their potential impact on the benefit-risk balance of Zydelig in the approved indications and relevant ongoing variations.
Maltese: Madankollu, fid-dawl tad-data emerġenti dwar is-sigurtà, il-Kummissjoni Ewropea (KE) qieset li s-sejbiet mill-provi kliniċi u d-data kollha disponibbli dwar is-sigurtà relatata ma' idelalisib għandha tiġi riveduta sabiex jiġi vvalutat l-impatt potenzjali tagħhom fuq il-bilanċ talbenefiċċju-riskju ta' Zydelig fl-indikazzjonijiet approvati u fil-varjazzjonijiet rilevanti li għaddejjin.
English: Further, if continuing with therapy, new risk minimisation (see below) should be implemented.
Maltese: Barra minn hekk, jekk titkompla t-terapija, għandhom jiġu implimentati miżuri ġodda tal-minimizzazzjoni tar-riskju (ara hawn taħt).
English: • The PRAC noted that the use of idelalisib in studies -0123, -0124 and -0125 was in different conditions than those currently authorised, and at earlier stages of the diseases.
Maltese: • Il-PRAC innota li l-użu ta' idelalisib fl-istudji -0123, -0124 u -0125 kien sar f'kundizzjonijiet differenti minn dawk attwalment awtorizzati, u fi stadji aktar bikrin tal-mard.
English: Whilst the matter is being further reviewed, the PRAC recommended as a provisional measure an update of the posology and warnings to take due account that treatment should not be initiated in patients with systemic infections, patients should be monitored for respiratory symptoms and be administered Pneumocystis jirovecii pneumonia prophylaxis.
Maltese: Filwaqt li l-kwistjoni qiegħda tkompli tiġi riveduta, bħala miżura provviżorja, il-PRAC irrakkomanda aġġornament tal-pożoloġija u tat-twissijiet sabiex jitqies bil-mod dovut li l-kura ma għandhiex tinbeda f'pazjenti b'infezzjonijiet sistemiċi, ilpazjenti għandhom jiġu mmonitorjati għal sintomi respiratorji u jingħataw profilassi għal pulmonite Pneumocystis jirovecii.
English: Grounds for PRAC recommendation
Maltese: Raġunijiet għar-rakkomandazzjoni tal-PRAC
English: Therefore, the PRAC recommended that idelalisib should not be initiated in patients with any evidence of ongoing systemic bacterial, fungal, or viral infection.
Maltese: Għalhekk, il-PRAC irrakkomanda li idelalisib ma għandux jinbeda f'pazjenti b'xi evidenza ta' infezzjoni batterika, fungali jew virali sistemika kontinwa.
English: Marketing authorisation holders of aprotinin containing medicinal products shall submit to the national competent authorities, further to the issuing of the Commission Decision and prior to relaunch of the medicinal product to the European market, an update of the risk management plan (RMP) referring to the agreed products' safety concerns as described in the assessment report of the referral procedure and their risk minimisation which includes a direct healthcare professional communication.
Maltese: Id-detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq ta' prodotti mediċinali li fihom aprotinin għandhom jissottomettu lill-awtoritajiet nazzjonali kompetenti, wara l-ħruġ tad-Deċiżjoni talKummissjoni u qabel mal-prodott mediċinali jerġa jitqiegħed fis-suq Ewropew, aġġornament talpjan tal-ġestjoni tar-riskju (RMP) li jirreferi għat-tħassib fir-rigward tas-sigurtà tal-prodotti miftiehma kif deskritt fir-rapport ta' evalwazzjoni tal-proċedura ta' riferiment u l-minimizzazzjoni tar-riskju tagħhom li jinkludi komunikazzjoni professjonali diretta tal-kura tas-saħħa.
English: Annex IV Conditions of the marketing authorisations
Maltese: Anness IV Kundizzjonijiet tal-awtorizzazzjonijiet għat-tqegħid fis-suq
English: A restricted distribution of aprotinin with the above mentioned registry, with aprotinin available only to centres that perform cardiac surgery on cardio-pulmonary bypass and that commit to participate in the registry.
Maltese: Ir-reġistru għandu jirreġistra informazzjoni dwar l-użu fuq pazjenti f'ċentri ta' kirurġija kardijaka esposti għal aprotinin fil-pajjiżi parteċipanti.
English: This RMP shall follow the EU RMP template and shall include the measures to assess the effectiveness of the risk minimisation.
Maltese: Dan l-RMP għandu jsegwi l-mudell tal-RMP tal-UE u għandu jinkludi l-miżuri biex tiġi evalwata l-effikaċja talminimizzazzjoni tar-riskju.
English: Updates on the registry will be submitted to national competent authorities with periodic safety update reports (PSURs).
Maltese: Aġġornamenti fil-reġistru għandhom jiġu sottomessi lill-awtoritajiet nazzjonali kompetenti flimkien ma' rapporti perjodiċi ta' aġġornament dwar is-sigurtà (PSURs).
English: National Competent Authorities shall ensure that the following conditions are fulfilled by the MAHs of aprotinin containing medicinal products:
Maltese: L-Awtoritajiet Nazzjonali Kompetenti għandhom jiżguraw li l-kundizzjonijiet li ġejjin jiġu sodisfatti mid-detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq ta' prodotti mediċinali li fihom aprotinin:
English: Marketing authorisation holders shall conduct a registry, in order to monitor the pattern of use of aprotinin.
Maltese: Id-detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq għandhom jagħmlu reġistru, sabiex jiġi mmonitorjat il-mudell tal-użu ta' aprotinin.
English: None.
Maltese: Xejn.
English: The full EPAR for Letifend can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: In a field study in France and Spain 275 dogs were vaccinated with Letifend and 274 dogs received placebo (a dummy vaccination).
Maltese: Fi studju prattiċi fi Franza u Spanja, 275 kelb tlaqqmu b'Letifend u 274 kelb irċevew plaċebo (tilqima finta).
English: This summary was last updated in February 2016.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi Frar 2016.
English: Letifend canine leishmaniasis vaccine (recombinant protein)
Maltese: Letifend tilqima kontra leishmaniasis tal-klieb (proteina rikombinanti)
English: Letifend contains the active substance protein Q, which is made of different fragments of proteins from Leishmania infantum.
Maltese: Letifend fih is-sustanza attiva proteina Q, li hija magħmula minn biċċiet differenti ta' proteini minn Leishmania infantum.
English: This is a summary of the European public assessment report (EPAR) for Letifend.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Letifend.
English: Letifend is a vaccine.
Maltese: Letifend huwa tilqima.
English: Why is Letifend approved?
Maltese: Għal xiex ġie approvat Letifend?
English: The parasite is widespread in countries bordering the Mediterranean Sea and is transmitted by the bites of sand flies.
Maltese: Il-parassit huwa komuni f'pajjiżi li jmissu mal-Baħar Mediterran u jiġi trażmess mill-gdim tas-sand flies.
English: The dogs were exposed to natural infection with Leishmania infantum.
Maltese: Il-klieb kienu esposti għal infezzjoni naturali b'Leishmania infantum.
English: Infected dogs can help spread the disease to humans.
Maltese: Annimali mhux infettati biss għandhom jitlaqqmu.
English: Over a two year period there were 8 confirmed cases of leishmaniasis in the vaccinated group compared with 19 cases in the placebo group, showing that Letifend was effective in reducing the occurrence of the disease.
Maltese: Fuq perjodu ta' sentejn kien hemm 8 każijiet ikkonfermati ta' leishmaniasis fil-grupp imlaqqam meta mqabbla ma' 19-il każ fil-grupp tal-plaċebo, fejn juri li Letifend kien effettiv fit-tnaqqis tal-okkorrenza tal-marda.
English: Letifend is a veterinary vaccine used in dogs to protect them against leishmaniasis due to the parasite Leishmania infantum.
Maltese: Letifend huwa tilqima veterinarja użata fil-klieb sabiex tħarishom kontra leishmaniasis minħabba lparassita Leishmania infantum.
English: Other information about Letifend?
Maltese: Informazzjoni oħra dwar Letifend
English: What are the risks associated with Letifend?
Maltese: X'inhuma r-riskji assoċjati ma' Letifend?
English: Dogs that have been infected may show no signs of infection, but some have active disease with symptoms such as fever, hair and weight loss, and skin sores.
Maltese: Il-klieb li ġew infettati jistgħu ma jurux sinjali ta' infezzjoni, iżda xi wħud għandhom marda attiva b'sintomi bħad-deni, telf tal-pil u l-piz, u selħiet fil-ġilda.
English: Letifend is available as a freeze-dried powder (lyophilisate) and solvent that are made up into a solution for injection, and can only be obtained with a prescription.
Maltese: Letfiend huwa disponibbli bħala trab imnixxef bil-friża (lyophilisate) u solvent li huma magħmulin f'sospensjoni għal injezzjoni, u jista' jinkiseb biss b'riċetta ta' tabib.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Letifend's benefits are greater than its risks and recommended that it be approved for use in the EU.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu Veterinarju (CVMP) tal-Aġenzija ddeċieda li l-benefiċċji ta' Letifend huma akbar mir-riskji tiegħu u rrakkomanda li jkun approvat għall-użu fl-UE.
English: In the future, if the animals are exposed to the parasite, the immune system will be able to respond more quickly.
Maltese: Jekk fil-futur l-annimali jkunu esposti għall-parassita, is-sistema immuni tkun kapaċi tirreaġixxi aktar malajr.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Maltese: It-tilqimiet jaħdmu billi "jgħallmu" lis-sistema immuni (id-difiżi naturali talġisem) kif tiddefendi ruħha kontra l-mard.
English: What benefits of Letifend have been shown in studies?
Maltese: X'inhuma l-benefiċċji ta' Letifend li ħarġu mill-istudji?
English: When Letifend is given to dogs the immune system recognises the Leishmania protein as ‘foreign' and makes defences against it.
Maltese: Meta Letifend jingħata lill-klieb is-sistema immunitarja tagħraf il-proteina ta' Leishmania bħala "barranija" u tagħmel difiżi kontriha.
English: Study 3a
Maltese: Studju 3a
English: EU/1/18/1309/001 EU/1/18/1309/002 EU/1/18/1309/003 EU/1/18/1309/004 EU/1/18/1309/005
Maltese: EU/1/18/1309/001 EU/1/18/1309/002 EU/1/18/1309/003 EU/1/18/1309/004
English: EU/1/18/1309/001 28 tablets EU/1/18/1309/002 84 tablets EU/1/18/1309/003 30 tablets EU/1/18/1309/004 28 tablets EU/1/18/1309/005 84 tablets
Maltese: EU/1/18/1309/001 28 pillola EU/1/18/1309/002 84 pillola EU/1/18/1309/003 30 pillola EU/1/18/1309/004 28 pillola EU/1/18/1309/005 84 pillola
English: P values: 1 = <0.001, 2 = 0.037, 3= <0.002, 4 = <0.006.
Maltese: Valuri P : 1 = <0.001, 2 = 0.037, 3= <0.
English: 17, rue de Pontoise F-95520 Osny France
Maltese: 17 rue de Pontoise F-95520
English: Patients in amenorrheab,c
Maltese: Pazjenti f'amenorreab,c
English: Patients with controlled bleedingb,c, d
Maltese: Pazjent bi fsada kkontrollatab,c,d